Pipeline

Commercialized Products

TAVALISSE® (fostamatinib)*

Adult Chronic Immune Thrombocytopenia (ITP)
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

TAVLESSE (fostamatinib) - Europe

Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • EMA Review
  • Approved

TAVALISSE (fostamatinib) - Canada

Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • HC Review
  • Approved

Fostamatinib in Global Markets

Fostamatinib - Israel

Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • HC Review
  • Approved

Fostamatinib - Japan/Asia

Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Japan Phase 3
  • Approved

Clinical Trials**

TAVALISSE (fostamatinib)

Warm Antibody AIHA
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Fostamatinib

COVID-19
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  •  
  •  
  • Phase 3
  • Approved

Fostamatinib – NIH/NHLBI***

COVID-19
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  •  
  • Phase 2
  • Phase 3
  • Approved

Fostamatinib – Imperial College London

COVID-19 
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  •  
  • Phase 2
  • Phase 3
  • Approved

R835

Immune Disease 
Target: Interleukin receptor associated kinases 1 and 4 (IRAK1/4)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

R552

Immune Disease
Target: Receptor-interacting protein kinase (RIP1)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Partnered-Sponsored Trials

Bemcentinib - BerGenBio

Oncology, COVID-19
Target: AXL receptor tyrosine kinase (AXL)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

DS-3032 - Daiichi Sankyo

Oncology
Target: Murine double minute 2 (MDM2)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

AZD0449 - AstraZeneca

Chronic Asthma
Target: Janus tyrosine kinase (JAK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved
  • Key:
  • Company-sponsored Trials
  • Select Investigator-sponsored Trials
  • Partner-sponsored Trials

* Please see the TAVALISSE full Prescribing Information
** Investigational compounds in these indications have not been submitted for FDA review
*** National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)

Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors